Hong Kong’s Biotech Listings Emerge From Two-Year Downturn With 18As Booming

Biotech and medtech startups based in the People’s Republic of China (P.R.C.) are flocking to Hong Kong to float. Meng Ding explains how a combination of listing reforms and an explosion of innovation in the Greater Bay Area have led to Hong Kong’s 18A process being popular for life sciences.

AI-Powered Drug Discovery Efforts Could Lead to New Treatments

Stephen Abreu, Sidley partner, talks to Colin Hill, CEO and Co-Founder of AI-powered drug discovery company Aitia, about how the use of AI is revolutionizing the biotech space.


Korean Biotechs Share Their Insights With Sidley At J.P. Morgan Healthcare Conference 2023

Josh Hofheimer reports the takeaways from Sidley’s co-hosted pitch day with KoreaBio and BioCentury at the J.P. Morgan Healthcare Conference. The session included key insights on entrepreneurial developments and an investor panel on macroeconomic challenges.